文献速递眼底病与葡萄膜炎

BNT162b2 mRNA新冠疫苗接种后葡萄膜炎:可能关联

UVEITIS AFTER THE BNT162b2 mRNA VACCINATION AGAINST SARS-CoV-2 INFECTION: A Possible Association.
PubMed 文献 · Retina · 2021-01-01

多中心回顾性研究描述BNT162b2 mRNA新冠疫苗接种后发生的葡萄膜炎病例。21例(23眼)平均年龄51.3岁,8例有葡萄膜炎病史,从接种到发病平均7.5±7.3天,多数为轻中度前葡萄膜炎,最终随访除2眼外完全缓解。

要点

  • 接种BNT162b2 mRNA疫苗后可能发生葡萄膜炎,平均潜伏期7.5±7.3天。
  • 最常见表现为轻中度前葡萄膜炎,也可发生多发性一过性白点综合征。
  • 多数病例最终完全缓解,一例严重前葡萄膜炎并玻璃体炎和黄斑水肿经玻璃体腔地塞米松注射后完全消退。

核心结论

  • BNT162b2 mRNA疫苗接种后可能发生葡萄膜炎,最常见为轻中度前葡萄膜炎。

研究设计与样本

  • 多中心回顾性研究,纳入21例(23眼)接种BNT162b2 mRNA疫苗后发生葡萄膜炎的患者。
  • 疫苗相关葡萄膜炎诊断依据世界卫生组织不良药物术语分类和Naranjo标准。

主要发现

  • 21例(23眼)平均年龄51.3岁(范围23-78岁),8例有葡萄膜炎病史,距上次发作中位时间1年(0.5-15年)。
  • 21例前葡萄膜炎中2例为双侧炎症;8例发生于第一次接种后,13例发生于第二次接种后。
  • 除3例外均表现为轻中度疾病;2例在第二次接种后发生多发性一过性白点综合征。
  • 从接种到葡萄膜炎发病平均时间7.5±7.3天(范围1-30天)。
  • 最终随访时除2眼外均完全缓解,2眼显著改善;1例严重前葡萄膜炎在第二次接种后出现玻璃体炎和黄斑水肿,经玻璃体腔地塞米松注射后完全消退。

临床怎么用

  • 接种BNT162b2 mRNA疫苗后出现眼部炎症时应考虑疫苗相关葡萄膜炎可能,多数为轻中度前葡萄膜炎且预后良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe uveitis cases after the BNT162b2 mRNA SARS-CoV-2 vaccination. METHODS: This is a multicenter, retrospective study. Vaccine-related uveitis diagnosis was supported by the classification of the World Health Organization Adverse Drug Terminology and the Naranjo criteria. RESULTS: Twenty-one patients (23 eyes) with a mean age of 51.3 years (23-78 years) were included. Eight of the 21 patients had a known history of uveitis. The median time from previous to current attack was 1 year (0.5-15 years). There were 21 anterior uveitis cases, two with bilateral inflammation. Eight cases occurred after the first vaccination and 13 after the second vaccination. All but three presented as mild to moderate disease. Two patients developed multiple evanescent white dot syndrome after the second vaccination. The mean time from vaccination to uveitis onset was 7.5 ± 7.3 days (1-30 days). At final follow-up, complete resolution was achieved in all but two eyes, which showed significant improvement. One case of severe anterior uveitis developed vitritis and macular edema after the second vaccination, which completely resolved after an intravitreal dexamethasone injection. CONCLUSION: Uveitis may develop after the administration of the BNT162b2 mRNA vaccine. The most common complication was mild to moderate anterior uveitis, while multiple evanescent white dot syndrome can also occur less frequently.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, et al. UVEITIS AFTER THE BNT162b2 mRNA VACCINATION AGAINST SARS-CoV-2 INFECTION: A Possible Association. Retina. 2021. PMID: 34369440. doi:10.1097/IAE.0000000000003277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。